Comparative Pharmacology
Head-to-head clinical analysis: MD 60 versus RENO 60.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MD 60 versus RENO 60.
MD-60 vs RENO-60
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
MD-60 is a nonionic iodinated contrast agent. It attenuates X-rays by increasing the density of structures and organs, improving radiographic visualization.
RENO-60 (diatrizoate meglumine and diatrizoate sodium) is an ionic, high-osmolality iodinated contrast agent. It attenuates X-rays by blocking photons due to the high atomic number of iodine, thereby enhancing vascular and tissue contrast. It distributes in extracellular fluid and is excreted unchanged by glomerular filtration.
Intravenous administration, 60 mg/kg as a single dose over 30 min.
Intravenous administration of 0.5-1.0 mL/kg (up to 150 mL total) per radiographic procedure. Dose may be repeated once if needed.
None Documented
None Documented
Terminal elimination half-life is 18–24 hours in patients with normal renal function (CrCl >90 mL/min); prolonged to >40 hours in moderate renal impairment (CrCl 30–60 mL/min), requiring dose adjustment.
Terminal elimination half-life approximately 30-60 minutes in patients with normal renal function; prolonged in renal impairment (up to 24 hours in anuria).
Primarily renal elimination of unchanged drug (~60% within 24 hours) via glomerular filtration; biliary/fecal excretion accounts for ~30% as metabolites; ~10% undergoes enterohepatic recirculation.
Primarily renal excretion via glomerular filtration; up to 20% excreted unchanged in urine within 24 hours; minor biliary/fecal (<5%).
Category C
Category C
Radiocontrast Agent
Radiocontrast Agent